AQR Capital Management LLC Cuts Stock Position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)

AQR Capital Management LLC lowered its holdings in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) by 45.3% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 60,005 shares of the biotechnology company's stock after selling 49,701 shares during the quarter. AQR Capital Management LLC owned approximately 0.28% of Enanta Pharmaceuticals worth $778,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the business. Rhumbline Advisers boosted its position in Enanta Pharmaceuticals by 4.7% during the second quarter. Rhumbline Advisers now owns 34,566 shares of the biotechnology company's stock worth $448,000 after purchasing an additional 1,548 shares in the last quarter. Allspring Global Investments Holdings LLC acquired a new position in shares of Enanta Pharmaceuticals during the second quarter valued at approximately $35,000. State Board of Administration of Florida Retirement System acquired a new position in shares of Enanta Pharmaceuticals during the first quarter valued at approximately $118,000. American Century Companies Inc. raised its holdings in shares of Enanta Pharmaceuticals by 35.4% during the second quarter. American Century Companies Inc. now owns 27,892 shares of the biotechnology company's stock valued at $362,000 after acquiring an additional 7,287 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its holdings in shares of Enanta Pharmaceuticals by 13.3% in the second quarter. Bank of New York Mellon Corp now owns 73,841 shares of the biotechnology company's stock valued at $958,000 after purchasing an additional 8,645 shares during the last quarter. Hedge funds and other institutional investors own 94.99% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the company. JPMorgan Chase & Co. cut their price target on Enanta Pharmaceuticals from $11.00 to $10.00 and set an "underweight" rating for the company in a report on Tuesday, August 6th. JMP Securities reaffirmed a "market outperform" rating and issued a $22.00 price target on shares of Enanta Pharmaceuticals in a report on Wednesday, October 9th. HC Wainwright reissued a "buy" rating and set a $27.00 target price on shares of Enanta Pharmaceuticals in a research note on Thursday. Finally, Evercore ISI raised Enanta Pharmaceuticals to a "strong-buy" rating in a research note on Tuesday, August 6th. One research analyst has rated the stock with a sell rating, two have given a hold rating, two have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $20.00.

Enanta Pharmaceuticals Stock Performance

Enanta Pharmaceuticals stock traded up $0.27 during mid-day trading on Monday, reaching $11.31. 110,798 shares of the company were exchanged, compared to its average volume of 207,073. The firm's 50-day simple moving average is $11.89 and its two-hundred day simple moving average is $13.14. Enanta Pharmaceuticals, Inc. has a twelve month low of $8.08 and a twelve month high of $17.80. The firm has a market cap of $239.53 million, a PE ratio of -1.81 and a beta of 0.58.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last issued its earnings results on Monday, August 5th. The biotechnology company reported ($1.07) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.43) by $0.36. Enanta Pharmaceuticals had a negative net margin of 160.27% and a negative return on equity of 63.75%. The company had revenue of $17.97 million during the quarter, compared to analysts' expectations of $17.44 million. During the same period last year, the company posted ($1.27) earnings per share. The firm's quarterly revenue was down 4.9% compared to the same quarter last year. As a group, equities research analysts anticipate that Enanta Pharmaceuticals, Inc. will post -5.3 EPS for the current year.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.